PCSK9 Inhibitors in Primary Cardiovascular Prevention: A Multi-Cohort Comparative Effectiveness Study of Evolocumab and Alirocumab versus Oral Dual Lipid-Lowering Therapy Using Real-World Electronic Health Records (AHA 2026) - Sep 5, 2026 - Abstract #Su3070; Pres time: Nov 8, 2026; 03:15 PM - 04:15 PM; Location: Population Science Zone, Science and Technology Hall, South Hall, Level 3; "Abstract is embargoed at this time."
Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular
|
|
Ahmad Assad, Univ of Central Florida, Gainesville, FL; Tala Altarawneh, Marshall Univ Sch of Med, Huntigton, WV; Abdallah Rayyan, Qusai Alqudah, Univ of Central Florida, Gainesville, FL; Ola Shaltout, Lahey Hosp and Medical Ctr, Boston, MA; Hamzeh Alshahwan, Univ of Central Florida / North Florida Hosp, Gainesville, FL; Adee Elhamdani, Marshall Univ Joan C Edwards Schl Med, Huntington, WV
|